Spotlight on ustekinumab in moderate to severe plaque psoriasis.

about

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

Item

http://www.wikidata.org/entity/Q48510956

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

@en

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

@nl

type

Item

label

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

@en

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

@nl

prefLabel

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

@en

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

@nl

P1476

Spotlight on ustekinumab in moderate to severe plaque psoriasis.

@en

P2093

Jamie D Croxtall

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab

Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies.

Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis.

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

P2888

11208650-000000000-00000

P304

135-137

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11208650-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1010955577

http://www.w3.org/2001/XMLSchema#string

P698

22201419

http://www.w3.org/2001/XMLSchema#string